Chabiotech

차바이오텍 · 085660

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$865.1M (₩1.2T)

Overview

Chabiotech stores umbilical cord blood, conducts stem-cell research, and develops cell-based therapies, treatments that use living cells to address disease, while also providing anti-aging services and related consulting.

Its customers include individuals and healthcare institutions that use these biological storage and therapeutic services. Through its principal subsidiaries, the company also operates in pharmaceuticals, global contract development and manufacturing (CDMO, where a firm handles drug development and production on behalf of other companies), and international medical-network services. Chabiotech is listed on KOSDAQ, South Korea's tech and small-cap exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$919M

▲ +21.4% YoY

Operating profit · FY2025

−US$35.3M

Loss narrowed

Net income · FY2025

−US$106.3M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$691.3M(₩954B)	US$757.3M(₩1T)	US$919M(₩1.3T)
Operating profit	−US$6.9M(−₩9.6B)	−US$43.2M(−₩59.7B)	−US$35.3M(−₩48.8B)
Net income	−US$4M(−₩5.6B)	−US$10.5M(−₩14.6B)	−US$106.3M(−₩146.7B)

Revenue

FY2023US$691.3M
FY2024US$757.3M
FY2025US$919M

Operating profit

FY2023−US$6.9M
FY2024−US$43.2M
FY2025−US$35.3M

Net income

FY2023−US$4M
FY2024−US$10.5M
FY2025−US$106.3M

Key ratios (FY2025)

ROE

-18.1%

Debt/Eq

214.8%

Op. margin

-3.9%

Net margin

-11.6%

Rev. YoY

▲ +21.4%

Why it matters

The company operates across multiple business lines through subsidiaries, spanning cord-blood banking, drug manufacturing services, and overseas medical networks under one consolidated group.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?